CSL traded at 287.22 this Thursday July 7th, increasing 1.09 or 0.38 percent since the previous trading session. Looking back, over the last four weeks, CSL gained 6.02 percent. Over the last 12 months, its price rose by 2.89 percent. Looking ahead, we forecast CSL to be priced at 262.98 by the end of this quarter and at 245.10 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
286.91
Daily Change
0.27%
Yearly
2.78%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
CSL 286.91 0.78 0.27% 2.78%

Indexes Price Day Year
AUALL 6802 17.70 0.26% -10.68%
AU50 6488 29.70 0.46% -8.58%
AU200 6614 19.71 0.30% -9.91%

CSL
CSL Limited is an Australia-based biotechnology company. The Company is engaged in developing and delivering biotherapies and influenza vaccines that treat people with serious diseases and chronic medical conditions. It offers treatments for people who are living with conditions in immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The Company operates through two segments: CSL Behring and Seqirus. CSL Behring manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early-stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. Its products include PRIVIGEN, IDELVION and AFSTYLA.